LYFE CAPITAL GLOBAL PARTNER LIMITED

Thesis

LYFE Capital is a global healthcare-focused investment firm founded in 2015, managing approximately USD 2 billion in assets. Their latest fund, Fund IV, closed in 2022 with USD 935 million. The firm invests exclusively in the healthcare sector, emphasizing critical supply chain assets, specialized product platforms, and next-generation R&D services, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and digital health. They target investments across early to growth stages (pre-seed to Series C) and also engage in private equity activities like buyouts and bolt-on acquisitions. LYFE Capital has a dual geographic focus on Asia (Singapore, South Korea, Japan) and the United States, aiming to combine Asia's cost benefits with U.S. innovation. Their strategy involves building 'healthcare champions' by leveraging global resources, talent, and operational streamlining. They drive returns through geographic revenue expansion and bolt-on acquisitions, often taking lead roles in investments. The firm has multiple offices globally, including Menlo Park (USA), Seoul (South Korea), Shanghai (China), Tokyo (Japan), and Singapore.

Related lists

• Pre-seed Healthcare investors
• Seed-stage Healthcare investors
• Series A Healthcare investors